Pathophysiological significance of c-jun N-terminal kinase in acetaminophen hepatotoxicity

Kuo Du1, Yuchao Xie1, Mitchell R McGill1

  • 1a University of Kansas Medical Center, Department of Pharmacology, Toxicology and Therapeutics , Kansas City, KS, USA +1 913 588 7969 ; +1 913 588 7501 ; hjaeschke@kumc.edu.

Abstract

Insights

Acetaminophen (APAP) overdose causes liver failure. While c-jun N-terminal Kinase (JNK) is a potential target, its role in APAP liver injury remains controversial, requiring further research.

Area of Science:

  • Hepatology
  • Toxicology
  • Molecular Biology

Background:

  • Acetaminophen (APAP) overdose is a primary cause of acute liver failure in the U.S.
  • Current therapeutic options for APAP-induced liver injury are limited, necessitating novel treatment strategies.
  • c-jun N-terminal Kinase (JNK) signaling pathways have been identified as a potential therapeutic target.

Purpose of the Study:

  • To review and reconcile conflicting findings regarding the role of JNK activation in APAP hepatotoxicity.
  • To critically evaluate the therapeutic potential of targeting JNK for APAP poisoning.

Main Methods:

  • Review of early and recent studies on JNK activation in APAP hepatotoxicity.
  • Analysis of discrepancies in findings related to JNK deficiency and inhibitor effects.
  • Examination of recent studies showing variable effects on liver injury independent of JNK activation.

Main Results:

  • Early studies suggested a critical role for JNK activation and mitochondrial translocation in APAP hepatotoxicity.
  • Subsequent studies failed to consistently reproduce the protective effects of JNK deficiency.
  • Recent research indicates that liver injury can be modulated with or without significant changes in JNK activation.

Conclusions:

  • JNK remains a potential therapeutic target for APAP poisoning.
  • Significant controversies persist regarding the precise role of JNK in APAP-induced liver injury.
  • Further investigation with specific inhibitors in preclinical models and human hepatocytes is essential to validate JNK as a therapeutic target.

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.3K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
69
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
176
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
114
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.9K